More on PGEN
Data
Upcoming Events
News
|
|||||
|---|---|---|---|---|---|
| Prev. Close | $4.73 |
|
|||
| Open | $4.76 | ||||
| 52 Wk High | $ | ||||
| 52 Wk Low | $ | ||||
| Day High | $4.87 | ||||
| Day Low | $4.59 | ||||
| P/E | N/A | ||||
| EPS | $ | ||||
| Volume | 4,755,744 | ||||
- Precigen receives FDA orphan drug exclusivity for PAPZIMEOS through 2032
- Precigen Gains Advantage as PAPZIMEOS Granted Orphan Drug Exclusivity by FDA; Long-Term Data From Clinical Study Encouraging
- Precigen and the Recurrent Respiratory Papillomatosis Foundation Recognize International RRP Awareness Day by Elevating Patient and Community Voices
- H.C. Wainwright Reiterates Buy Rating on Precigen Inc. (PGEN)
- Form 4 PRECIGEN, INC. For: May 28 Filed by: Thomasian Harry Jr.
- Form 4 PRECIGEN, INC. For: May 28 Filed by: Tennant Phil
- Form 4 PRECIGEN, INC. For: May 28 Filed by: Shah Rutul R
- Form 4 PRECIGEN, INC. For: May 28 Filed by: Lehr Donald P.
- Form 4 PRECIGEN, INC. For: May 28 Filed by: Sabzevari Helen
- Precigen Presents New Long-Term Durability Data for PAPZIMEOS, Recently Granted Seven-Year Market Exclusivity, Demonstrating Complete Responses Beyond 4 Years
Entities mentioned with PGEN
- FDA | View Related Stories »
- Twitter | View Related Stories »
- Earnings | View Related Stories »
- Maynard Um | View Related Stories »
- Mark Zuckerberg | View Related Stories »
- ARK | View Related Stories »
- JPMorgan | View Related Stories »
- H.C. Wainwright | View Related Stories »
- Show More...
